

**AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior versions, and listings of claims in the present application.

**Listing of Claims:**

Claim 1 (previously presented) A method of treatment comprising improving and/or normalizing lung function in a patient in need of said treatment, said method comprising administering an amount of recombinant human uteroglobin comprising the amino acid sequence of SEQ ID NQ 1 to said patient sufficient to improve and/or normalize lung function relative to lung function in the absence of said treatment.

Claim 2 (previously presented) The method of claim 1 wherein said recombinant human uteroglobin comprises the amino acid sequence of SEQ ID NO 1 having the amino acid sequence Ala-Ala added to the N-terminus of SEQ ID NO 1.

Claim 3 (previously presented) The method of claim 1 wherein said amount of recombinant human uteroglobin is 10 ng/kg ofbody weight - 25 mg/kg ofbody weight.

Claim 4 (previously presented) A method of treatment comprising improving and/or normalizing pulmonary compliance in a patient in need of said treatment, said method comprising administering an amount of recombinant human uteroglobin comprising the amino acid sequence of SEQ ID NO 1 to said patient sufficient to improve and/or normalize pulmonary compliance relative to pulmonary compliance in the absence of said treatment.

Claim 5 (original) The method of claim 4 wherein said patient suffers from reduced pulmonary compliance as a result of a pulmonary challenge or insult resulting from exposure to one or more substances selected from the group consisting of non-atmospheric gases, nonatmospheric ratios of atmospheric gases, inhaled chemicals, pollutants, irritants, inhaled pollens, allergens, particulate matter, and an airborne infectious agent.

Claim 6 (previously presented) The method of claim 4 wherein said recombinant human uteroglobin comprises the amino acid sequence of SEQ ID NO 1 having the amino acid sequence Ala-Ala added to the N-terminus of SEQ ID NO 1.

Claim 7 (previously presented) The method of claim 4 wherein said amount of recombinant human uteroglobin is 10 ng/kg of body weight - 25 mg/kg of body weight.

Claim 8 (previously presented) A method of treatment comprising improving blood oxygenation and/or normalizing blood pH in a patient in need of said treatment, said method comprising administering to said patient an amount of recombinant human uteroglobin comprising the amino acid sequence of SEQ ID NQ 1 sufficient to improve blood oxygenation and/or normalize blood pH relative to blood oxygenation and/or blood pH in the absence of said treatment.

Claim 9 (previously presented) The method of claim 8 wherein said recombinant human uteroglobin comprises the amino acid sequence of SEQ ID NQ 1 having the amino acid sequence Ala-Ala added to the N-terminus of SEQ ID NO 1.

Claim 10 (previously presented) The method of claim 8 wherein said amount of recombinant human uteroglobin is 10 ng/kg of body weight - 25 mg/kg of body weight.

Claims 11-88 (canceled)

Claim 89 (previously presented) A method of treatment comprising improving and/or normalizing lung function in a patient in need of said treatment, said method comprising administering an amount of recombinant human uteroglobin to said patient sufficient to improve and/or normalize lung function relative to lung function in the absence of said treatment.

Claim 90 (previously presented) The method of claim 89 wherein said amount of recombinant human uteroglobin is 10 ng/kg of body weight - 25 mg/kg of body weight.

Claim 91 (previously presented) A method of treatment comprising improving and/or normalizing pulmonary compliance in a patient in need of said treatment, said method comprising administering an amount of recombinant human uteroglobin to said patient sufficient to improve and/or normalize pulmonary compliance relative to pulmonary compliance in the absence of said treatment.

Claim 92 (previously presented) The method of claim 91 wherein said patient suffers from reduced pulmonary compliance as a result of a pulmonary challenge or insult resulting from exposure to one or more substances selected from the group consisting of non-atmospheric gases, nonatmospheric ratios of atmospheric gases, inhaled chemicals, pollutants, irritants, inhaled pollens, allergens, particulate matter, and an airborne infectious agent.

Claim 93 (previously presented) The method of claim 91 wherein said amount of recombinant human uteroglobin is 10 ng/kg of body weight - 25 mg/kg of body weight.

Claim 94 (previously presented) A method of treatment comprising improving blood oxygenation and/or normalizing blood pH in a patient in need of said treatment, said method comprising administering to said patient an amount of recombinant human uteroglobin sufficient to improve blood oxygenation and/or normalize blood pH relative to blood oxygenation and/or blood pH in the absence of said treatment.

Claim 95 (previously presented) The method of claim 94 wherein said amount of recombinant human uteroglobin is 10 ng/kg of body weight - 25 mg/kg of body weight.

Claim 96 (new) The method of claim 5 wherein said nonatmospheric ratios of atmospheric gases comprises elevated oxygen delivery.